Atai & Beckley Psychedelic Merger Creates Global Mental Health Leader
Atai Life Sciences and Beckley Psytech are merging in an all-stock transaction, creating atai Beckley, a leading mental health...
Atai Life Sciences and Beckley Psytech are merging in an all-stock transaction, creating atai Beckley, a leading mental health...
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology announced positive Phase 2b results from the REZILIENT1 trial of zipalertinib, an...
ABLi Therapeutics recently completed an End of Phase 2 meeting with the FDA to discuss results from their Parkinson’s...
As GenAI gains traction across life sciences, the conversation is rapidly shifting from potential to practicality. Yet, many organizations...
In this interview, Anca Copaescu, Founder and CEO at Strategikon, explores the complexities of clinical trial management. Anca provides...
Ascendis Pharma A/S released 214-week data from its Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) for adults...
PDS Biotechnology Corporation announced preclinical data on its investigational Infectimune®-based flu vaccine at the IMMUNOLOGY2025™ Annual Meeting. Studies conducted...
Alzamend Neuro is partnering with QMENTA to utilize their AI-driven imaging platform in five upcoming Phase II clinical trials...
At SCOPE Summit 2025, a panel discussion explored the industry’s macro trends, focusing on AI, innovation, and outsourcing strategies....
Annexon, Inc. presented Phase 3 trial data for tanruprubart (formerly ANX005), a C1q-blocking monoclonal antibody, at the 2025 AAN...